文献速递慢阻肺肺结节与肺癌

CHRNA5 rs16969968 AA基因型独立增加肺癌、慢阻肺及吸烟强度风险

Chr15q25 genetic variant (rs16969968) independently confers risk of lung cancer, COPD and smoking intensity in a prospective study of high-risk smokers.
PubMed 文献 · Thorax · 2021-01-08

基于美国国家肺癌筛查试验中9270名高危吸烟者、平均随访6.4年的前瞻性研究,重新检验CHRNA5变异(rs16969968 AA基因型)与肺癌、慢阻肺和吸烟的关系。结果显示AA基因型与肺功能较低、吸烟强度更高、慢阻肺存在及肺癌发生相关,中介分析提示其对吸烟强度、慢阻肺和肺癌均有独立关联。

要点

  • AA基因型与较低肺功能、较高吸烟强度、慢阻肺及肺癌发生相关。
  • 中介分析显示AA基因型独立关联吸烟强度、慢阻肺和肺癌。
  • 该变异可能同时影响吸烟行为、慢阻肺和肺癌风险。

核心结论

  • 在高危吸烟者前瞻性队列中,CHRNA5 rs16969968 AA基因型独立关联吸烟暴露、慢阻肺和肺癌,呈三重效应。

研究设计与样本

  • 研究纳入美国国家肺癌筛查试验中9270名非西班牙裔白人高危吸烟者,平均随访6.4年。
  • 比较不同CHRNA5基因型者的基线吸烟暴露、肺功能和慢阻肺状态,并比较肺癌发病率。
  • 采用多元逻辑回归和中介分析检验AA基因型在吸烟暴露、慢阻肺和肺癌中的作用。

主要发现

  • AA高危基因型与较低肺功能相关(p=0.005)。
  • AA高危基因型与较高吸烟强度相关(p<0.001)。
  • AA高危基因型与慢阻肺存在相关(OR 1.28,95%CI 1.10-1.49,p=0.0015)。
  • AA高危基因型与肺癌发生相关(HR 1.41,95%CI 1.03-1.93,p=0.03)。
  • 中介分析中AA基因型独立关联吸烟强度(OR 1.42,95%CI 1.25-1.60,p<0.0001)、慢阻肺(OR 1.25,95%CI 1.66-2.53,p=0.0015)和肺癌(OR 1.37,95%CI 1.03-1.82,p=0.03)。

临床怎么用

  • 对高危吸烟者,CHRNA5 rs16969968 AA基因型可能提示需更关注吸烟强度、肺功能下降及慢阻肺和肺癌风险。

局限性

  • 研究对象限于非西班牙裔白人高危吸烟者,结果外推需谨慎。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: While cholinergic receptor nicotinic alpha 5 (CHRNA5) variants have been linked to lung cancer, chronic obstructive pulmonary disease (COPD) and smoking addiction in case-controls studies, their corelationship is not well understood and requires retesting in a cohort study. OBJECTIVE: To re-examine the association between the CHRNA5 variant (rs16969968 AA genotype) and the development of lung cancer, relative to its association with COPD and smoking. METHODS: In 9270 Non-Hispanic white subjects from the National Lung Screening Trial, a substudy of high-risk smokers were followed for an average of 6.4 years. We compared CHRNA5 genotype according to baseline smoking exposure, lung function and COPD status. We also compared the lung cancer incidence rate, and used multiple logistic regression and mediation analysis to examine the role of the AA genotype of the CHRNA5 variant in smoking exposure, COPD and lung cancer. RESULTS: As previously reported, we found the AA high-risk genotype was associated with lower lung function (p=0.005), greater smoking intensity (p<0.001), the presence of COPD (OR 1.28 (95% CI 1.10 to 1.49) p=0.0015) and the development of lung cancer (HR 1.41, (95% CI 1.03 to 1.93) p=0.03). In a mediation analyses, the AA genotype was independently associated with smoking intensity (OR 1.42 (95% CI 1.25 to 1.60, p<0.0001), COPD (OR 1.25, (95% CI 1.66 to 2.53), p=0.0015) and developing lung cancer (OR 1.37, (95% CI 1.03 to 1.82) p=0.03). CONCLUSION: In this large-prospective study, we found the CHRNA5 rs 16 969 968 AA genotype to be independently associated with smoking exposure, COPD and lung cancer (triple whammy effect).

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Hopkins RJ, Duan F, Gamble GD, et al. Chr15q25 genetic variant (rs16969968) independently confers risk of lung cancer, COPD and smoking intensity in a prospective study of high-risk smokers. Thorax. 2021. PMID: 33419953. doi:10.1136/thoraxjnl-2020-214839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。